FLGT vs GH
FLGT: Fulgent Genetics is a diagnostic laboratory that leverages proprietary technology to provide accessible, affordable, and actionable genetic testing for rare diseases, cancer, and reproductive health. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | FLGT | GH | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $16.55 | $161.99 | |
| Market cap as of 2026-08-03 | $455M | $21.7B | |
| PEG as of 2026-08-03 | -0.10 | -9.46 | GH lower |
| Net margin as of 2026-08-03 | -23.0% | -40.1% | FLGT higher |
| Gross margin as of 2026-08-03 | +38.7% | +64.9% | GH higher |
| Operating margin as of 2026-08-03 | -36.2% | -42.7% | FLGT higher |
| ROE as of 2026-08-03 | -6.7% | -246.6% | FLGT higher |
| ROA as of 2026-08-03 | -6.2% | -26.5% | FLGT higher |
| Debt / equity as of 2026-08-03 | 0.00 | 16.78 | FLGT lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.5% | +39.6% | GH higher |
| Revenue CAGR (3y) SEC XBRL | -19.5% | +29.8% | GH higher |
| Beta as of 2026-08-03 | 0.67 | 1.21 | |
| 1-year return as of 2026-07-31 close | -3.7% | +295.3% | GH higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.